Form 4: Abbott Laboratories Executive Vice President Exercises Stock Options and Sells Shares

Daniel Gesua Sive Salvadori, an Executive Vice President at Abbott Laboratories, exercised stock options and sold a portion of the acquired shares on January 30, 2025.

Summary

• On January 30, 2025, Daniel Gesua Sive Salvadori, an Executive Vice President at Abbott Laboratories, exercised stock options to acquire 23,771 common shares at a price of $38.4 per share.
• Following the exercise of the options, Mr. Salvadori sold the same 23,771 shares at a price of $128.5 per share.
• After these transactions, Mr. Salvadori directly owns 125,697 common shares of Abbott Laboratories.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction, not indicative of any positive or negative sentiment towards the company's performance.

Industry Context

This is a routine transaction for an executive exercising stock options and selling shares, which is common in publicly traded companies. It is a standard part of executive compensation.

Comparison to Industry Standards

• Executive stock option exercises and sales are a common practice across publicly traded companies, particularly in the pharmaceutical and medical device industries.
• The timing and pricing of these transactions are often dictated by vesting schedules and market conditions.
• Similar transactions are regularly reported by executives at companies like Medtronic, Johnson & Johnson, and Boston Scientific.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a standard executive stock option exercise and sale.

Key Dates

Keywords

Abbott Laboratories, Stock Options, Executive Stock Sale, Form 4, Insider Trading, Daniel Gesua Sive Salvadori